How another firm's FDA approval could mean a big win for Denali Therapeutics
Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...
Winners and wishers: 8 potential Bay Area drug approvals coming this year
Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...
Nasdaq closes higher with Trump's tariffs on deck
The Nasdaq Composite (^IXIC) closed 150 points higher as Wall Street anxiously awaits President Trump's tariff plans. Market ...
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T ...
Greenwich Life rises on data from late-stage trial for breast cancer vaccine
Greenwich LifeSciences (GLSI) stock surges 23% premarket after promising Phase 3 results for GLSI-100, a breast cancer ...
BioPharma Dive2h
Newly launched genetic medicine CDMO acquires Landmark Bio
Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene and cell therapies.
Grove AI Welcomes Former Novartis, UCB, and Google Executives to Company Advisory Board
The Grove AI Advisory Board brings together distinguished experts in global pharmaceutical strategy, AI innovation, and regulatory compliance. Advisory members will collaborate directly with Grove ...
NC Biotech23h
FDA clears Precision BioSciences to begin trials of gene-editing treatment for hepatitis B
Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...